Selective Enrichment of A-To-I Edited Transcripts from Cellular RNA Using Endonuclease V

Application

Kit to efficiently identify and enrich adenosine-to-inosine (A-to-I) editing in RNA molecules.

Key Benefits

  • Robust and facile method for enriching A-to-I edited transcripts.
  • Overcomes the low efficiency and accuracy of transcriptome-wide RNA-seq.

Market Summary

A-to-I RNA editing by adenosine deaminases is a common RNA modification of double-stranded RNA. RNA editing plays critical roles in RNA metabolism, and may also be involved in cancer, aging and/or autoimmune diseases. Accurate identification and effective editing rate are necessary to understanding the effect of A-to-I RNA editing on regulation of epitranscriptome and relationships with disease. Recent developments in next generation RNA sequencing (RNA-seq) allow researchers to detect A-to-I editing. However, current RNA-seq technique is still inefficient and prone to error, underscoring the need for a simple, but robust method to enrich A-to-I edited transcripts. Currently, there are no robust methods of inosine-containing transcripts based on affinity purification.

Technical Summary

Emory researchers have developed a method to selectively isolate A-to-I edited RNAs using Endonuclease V (eEndoV), called EndoVIPER (Endonuclease V inosine precipitation enrichment). By changing levels of Mg2+ and Ca2+, eEndoV catalysis can be switched from cleaving to promoting binding of inosine, enabling pulldown of A-to-I edited transcripts with high affinity and high specificity. They demonstrated that EndoVIPER enables isolation and enrichment of A-to-I edited transcripts from cellular RNA (brain mRNA). This method offers a robust and facile workflow for A-to-I identification and enrichment, helping to understand the regulation of A-to-I editing in a range of biological functions and disease processes.

Developmental Stage

In vitro experiments have been demonstrated with full RNA-seq validation of human brain mRNA.

Publication: Knutson, S. et al. (2019). BioRxiv.

Patent Information

App Type Country Serial No. Patent No. File Date Issued Date Patent Status
Nationalized PCT - United States United States 17/425,698   7/23/2021   Pending
Tech ID: 19090
Published: 12/3/2019